According to DelveInsight's analysis, the current
developmental pipeline for opioid withdrawal syndrome has multiple
players; several companies have initiated clinical trials
investigating new treatment options or studying how to use existing
treatment options better. The dynamics of the opioid withdrawal
syndrome market are also anticipated to change in the coming years,
owing to the rise in healthcare spending globally.
LAS
VEGAS, May 1, 2024 /PRNewswire/ --
DelveInsight's Opioid Withdrawal Syndrome Market
Insights report includes a comprehensive understanding of
current treatment practices, opioid withdrawal syndrome emerging
drugs, market share of individual therapies, and current and
forecasted market size from 2020 to 2034, segmented into 7MM
[the United States, the EU4
(Germany, France, Italy, and Spain) and the United Kingdom, and Japan].
Key Takeaways from the Opioid Withdrawal Syndrome Market
Report
- According to DelveInsight's analysis, the market size for
opioid withdrawal syndrome reached USD 1.3 billion in 2022 across the 7MM.
- Among the 7MM, the US captured the highest market in 2022,
covering a total of 90% market, followed by the UK, which is
anticipated to grow during the forecast period (2023–2034).
- In the US, the market mainly consisted of opioid
agonist-antagonist, Alpha-2 adrenergic agonists and others, which
generated nearly USD 1.1
million in 2022.
- According to DelveInsight estimations, nearly 9 million
cases with long-term opioid usage were found in 2022 in the
7MM.
- Leading opioid withdrawal syndrome companies such as
DemeRx IB, Inc., atai Life Sciences, MediciNova, BioXcel
Therapeutics Inc., and others are developing novel opioid
withdrawal syndrome drugs that can be available in the opioid
withdrawal syndrome market in the coming years.
- The promising opioid withdrawal syndrome therapies in the
pipeline include DMX-1002 (Ibogaine HCl), MN-166,
BXCL501, and others.
Discover which therapies are expected to grab the major opioid
withdrawal syndrome market share @ Opioid Withdrawal
Syndrome Market Report
Opioid Withdrawal Syndrome Overview
Opioid withdrawal is a set of symptoms that occurs when opioids
(such as µ-receptor agonists) are suddenly stopped, their use is
reduced, or they are no longer taken for treatment. This can also
happen when an opioid antagonist (like naltrexone or naloxone) or,
in some cases, a partial opioid agonist (such as buprenorphine) is
given to someone who has become physically dependent on opioids due
to regular and persistent use. There isn't a specific test to
diagnose opioid withdrawal, but it's important to conduct urine
toxicology tests to rule out withdrawal from other drugs or
combinations of drugs.
Urine tests usually detect most opioids like morphine, heroin,
codeine, oxycodone, and propoxyphene for about 12 to 36 hours after
their use. However, methadone, buprenorphine, and LAAM
(L-alpha-acetylmethadol) won't show up in standard urine tests for
opioids and need specific testing. Additionally, urine tests for
other substances like marijuana, cocaine, benzodiazepines, and
amphetamines may often show positive results in opioid users. Other
tests such as ECG, complete blood count (CBC), blood alcohol
levels, and basic metabolic panel (BMP) should also be conducted.
The severity of opioid withdrawal is commonly assessed using the
Clinical Opioid Withdrawal Scale (COWS).
Opioid Withdrawal Syndrome Epidemiology Segmentation
As per DelveInsight's estimations, the total number of cases
with opioid withdrawal syndrome in the
United States were approximately 7 million in 2022
and are projected to decrease during the forecast
period.
The opioid withdrawal syndrome market report proffers
epidemiological analysis for the study period 2020–2034 in the 7MM
segmented into:
- Number of Opioid Misuse Cases
- Number of Cases with Long-term Opioid Usage
- Total Opioid Withdrawal Symptoms Cases
Opioid Withdrawal Syndrome Treatment Market
The management of opioid use disorder and opioid withdrawal
syndrome are intricately linked since they tackle various facets of
the same fundamental problem: dependency on opioids and the
difficulties it brings. Opioid use disorder treatment is centered
on enduring control and recovery from opioid addiction, whereas
opioid withdrawal syndrome treatment mainly deals with the
immediate symptoms that emerge when people try to lessen or stop
their opioid use. A successful approach to handling OWS is
frequently a vital part of OUD treatment, especially during the
detoxification stage when individuals might undergo severe
withdrawal symptoms.
Drugs employed to ease OWS can also contribute to treating OUD
by aiding individuals in moving from reliance on opioids towards
stability and eventual abstinence. These medications not only
alleviate withdrawal signs but also diminish cravings, facilitating
individuals' participation in behavioral therapies and other
components of comprehensive OUD treatment.
The management strategy for OWS varies depending on how severe
the symptoms are for the person. When the withdrawal symptoms are
mild, patients are advised to focus on staying hydrated by drinking
at least 2–3 liters of water each day. Additionally, taking vitamin
B and C supplements may be helpful in maintaining overall health.
Generally, managing mild symptoms involves providing symptomatic
treatment and supportive care, aiming to ease discomfort and ensure
the patient's well-being during this period.
In instances of greater severity, drugs such as methadone or
codeine phosphate might be contemplated, especially for those
needing detoxification from opioids with longer-lasting effects.
These medications can ease withdrawal symptoms and diminish
cravings, but cautious supervision and dosage adjustments are vital
to ensure safety and efficacy.
To know more about opioid withdrawal syndrome treatment
guidelines, visit @ Opioid Withdrawal Syndrome
Management
Opioid Withdrawal Syndrome Pipeline Therapies and Key
Companies
- DMX-1002 (Ibogaine HCl): DemeRx IB, Inc./atai Life
Sciences
- MN-166: MediciNova
- BXCL501: BioXcel Therapeutics Inc.
Learn more about the FDA-approved drugs for opioid withdrawal
syndrome @ Drugs for Opioid Withdrawal Syndrome
Treatment
Opioid Withdrawal Syndrome Market Dynamics
The dynamics of the opioid withdrawal syndrome market are
expected to change in the coming years. Globally, the
recognition of the opioid crisis and the necessity for
effective treatments, including medications and behavioral
therapies, has prompted pharmaceutical companies to invest in
research and development, while government
initiatives prioritize opioid withdrawal management, fostering
opioid withdrawal syndrome market growth and opportunities for
companies.
The shift towards precision medicine also offers
possibilities for developing targeted treatments, addressing
the high prevalence of opioid addiction, and creating
significant market demand for withdrawal syndrome treatments,
potentially leading to substantial growth with the introduction
of therapies featuring novel mechanisms, alongside the
dominance of buprenorphine-based products in the current and
emerging opioid withdrawal syndrome market.
Furthermore, many potential therapies are being investigated for
the treatment of opioid withdrawal syndrome, and it is safe to
predict that the treatment space will significantly impact the
opioid withdrawal syndrome market during the forecast period.
Moreover, the anticipated introduction of emerging therapies
with improved efficacy and a further improvement in the
diagnosis rate are expected to drive the growth of the opioid
withdrawal syndrome market in the 7MM.
However several factors may impede the growth of the opioid
withdrawal syndrome market. The stigma surrounding opioid
addiction and withdrawal persists, potentially dissuading
individuals from pursuing treatment or utilizing the resources
available to them, despite advancements. The range of treatments
for opioid withdrawal syndrome is still somewhat limited,
necessitating more effective and accessible options. Stringent
regulatory requirements and lengthy approval processes could
delay the introduction of new OWS therapies to the market,
hampering innovation, while economic downturns or changes in
healthcare policies might impact funding for opioid
addiction treatment programs and access to care, posing a threat to
the OWS market and potentially compromising patient care and
therapeutic effectiveness.
Moreover, opioid withdrawal syndrome treatment poses a
significant economic burden and disrupts patients' overall
well-being and QOL. Furthermore, the opioid withdrawal
syndrome market growth may be offset by failures and
discontinuation of emerging therapies, unaffordable
pricing, market access and reimbursement issues, and a
shortage of healthcare specialists. In addition, the
undiagnosed, unreported cases and the unawareness about the
disease may also impact the opioid withdrawal syndrome market
growth.
Opioid Withdrawal
Syndrome Market Report Metrics
|
Details
|
Study Period
|
2020–2034
|
Coverage
|
7MM [the United States,
the EU4 (Germany, France, Italy, and Spain) and the United Kingdom,
and Japan].
|
Opioid Withdrawal
Syndrome Market CAGR
|
4.0 %
|
Opioid Withdrawal
Syndrome Market Size in
2022
|
USD 1.3
Billion
|
Key Opioid Withdrawal
Syndrome Companies
|
DemeRx IB, Inc., atai
Life Sciences, MediciNova, BioXcel Therapeutics Inc.,
and others
|
Key Pipeline Opioid Withdrawal Syndrome
Therapies
|
DMX-1002 (Ibogaine
HCl), MN-166, BXCL501, and
others
|
Scope of the Opioid Withdrawal
Syndrome Market Report
- Therapeutic Assessment: Opioid Withdrawal
Syndrome current marketed and emerging therapies
- Opioid Withdrawal Syndrome Market
Dynamics: Key Market Forecast Assumptions of Emerging
Opioid Withdrawal Syndrome Drugs and Market Outlook
- Competitive Intelligence Analysis: SWOT analysis
and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Opioid Withdrawal
Syndrome Market Access and Reimbursement
Discover more about opioid withdrawal syndrome drugs in
development @ Opioid Withdrawal Syndrome Clinical Trials
Table of Contents
1
|
Key Insights
|
2
|
Report
Introduction
|
3
|
Opioid Withdrawal
Syndrome Market Overview at a Glance
|
3.1
|
Market Share (%)
Distribution by Therapies of OWS in 2020
|
3.2
|
Market Share (%)
Distribution by Therapies of OWS in 2034
|
4
|
Epidemiology and Market
Methodology of OWS
|
5
|
Executive
Summary
|
6
|
Key Events
|
7
|
Opioid Withdrawal
Syndrome: Disease Background and Overview
|
7.1
|
Introduction
|
7.2
|
Etiology
|
7.3
|
Pathophysiology
|
7.4
|
Diagnosis
|
7.4.1
|
Differential
Diagnosis
|
7.4.2
|
Diagnostic
Algorithm
|
7.4.3
|
Diagnostic
Guidelines
|
7.4.3.1
|
DSM-5 Diagnostic
Criteria for Opioid Withdrawal
|
7.5
|
Management
|
7.5.1
|
Treatment
Algorithm
|
7.5.2
|
Treatment
Guidelines
|
7.5.2.1
|
The ASAM (American
Society of Addiction Medicine) National Practice Guideline for the
Use of Medications in the Treatment of Addiction Involving Opioid
Use
|
8
|
Epidemiology and
Patient Population
|
8.1
|
Key Findings
|
8.2
|
Assumptions and
Rationale
|
8.3
|
Total Opioid Withdrawal
Syndrome Cases in the 7MM
|
8.4
|
The United
States
|
8.4.1
|
Number of Opioid Misuse
Cases in the US
|
8.4.2
|
Number of Long-term
Opioid Usage Cases in the US
|
8.4.3
|
Total Opioid Withdrawal
Syndrome Cases in the US
|
8.5
|
EU4 and the
UK
|
8.5.1
|
Number of Opioid Misuse
Cases in EU4 and the UK
|
8.5.2
|
Number of Long-term
Opioid Usage Cases in EU4 and the UK
|
8.5.3
|
Total Opioid Withdrawal
Syndrome Cases in EU4 and the UK
|
8.6
|
Japan
|
8.6.1
|
Number of Opioid Misuse
Cases in Japan
|
8.6.2
|
Number of Long-term
Opioid Usage Cases in Japan
|
8.6.3
|
Total Opioid Withdrawal
Syndrome Cases in Japan
|
9
|
Patient
Journey
|
10
|
Marketed
Drugs
|
10.1
|
Key Cross Competition
of Marketed Drugs
|
10.2
|
LUCEMYRA (lofexidine
hydrochloride): US World Meds LLC
|
10.2.1
|
Drug
Description
|
10.2.2
|
Regulatory
Milestones
|
10.2.3
|
Other Developmental
Activities
|
10.2.4
|
Clinical
Development
|
10.2.5
|
Clinical Trials
Information
|
10.2.6
|
Safety and
Efficacy
|
10.2.7
|
Product
profile
|
10.3
|
BRIXADI/BUVIDAL:
Braeburn Pharmaceuticals/Camurus
|
10.3.1
|
Drug
Description
|
10.3.2
|
Regulatory
Milestones
|
10.3.3
|
Other Developmental
Activities
|
10.3.4
|
Clinical
Development
|
10.3.5
|
Clinical Trials
Information
|
10.3.6
|
Safety and
Efficacy
|
10.3.7
|
Product
Profile
|
10.4
|
PROBUPHINE/SIXMO: Titan
Pharmaceuticals/Molteni Farmaceuticci
|
10.4.1
|
Drug
Description
|
10.4.2
|
Regulatory
Milestones
|
10.4.3
|
Other Developmental
Activities
|
10.4.4
|
Clinical Developmental
Activities
|
10.4.5
|
Clinical Trials
information
|
10.4.6
|
Safety and
Efficacy
|
10.4.7
|
Product
profile
|
10.5
|
SUBLOCADE:
Indivior
|
10.5.1
|
Product
Description
|
10.5.2
|
Regulatory
milestones
|
10.5.3
|
Other Developmental
Activities
|
10.5.4
|
Clinical Developmental
Activities
|
10.5.5
|
Clinical Trials
Information
|
10.5.6
|
Safety and
Efficacy
|
10.5.7
|
Product
Profile
|
10.6
|
ZUBSOLV:
Orexo
|
10.6.1
|
Product
Description
|
10.6.2
|
Regulatory
milestones
|
10.6.3
|
Other Developmental
Activities
|
10.6.4
|
Clinical Developmental
Activities
|
10.6.5
|
Clinical Trials
Information
|
10.6.6
|
Safety and
Efficacy
|
10.6.7
|
Product
Profile
|
10.7
|
VIVITROL:
Alkermes
|
10.7.1
|
Product
Description
|
10.7.2
|
Regulatory
milestones
|
10.7.3
|
Other Developmental
Activities
|
10.7.4
|
Clinical Developmental
Activities
|
10.7.5
|
Clinical Trials
Information
|
10.7.6
|
Safety and
Efficacy
|
10.7.7
|
Product
Profile
|
11
|
Emerging
Drugs
|
11.1
|
Key Cross Competition
of Emerging Therapies
|
11.2
|
DMX-1002 (Ibogaine
HCl): DemeRx IB, Inc./atai Life Sciences
|
11.2.1
|
Product
Description
|
11.2.2
|
Other Development
Activities
|
11.2.3
|
Clinical
Development
|
11.2.4
|
Clinical Trials
Information
|
11.2.5
|
Safety and
Efficacy
|
11.2.6
|
Product
Profile
|
11.2.7
|
Analysts'
Views
|
11.3
|
MN-166:
MediciNova
|
11.3.1
|
Product
Description
|
11.3.2
|
Other Development
Activities
|
11.3.3
|
Clinical
Development
|
11.3.4
|
Clinical Trials
Information
|
11.3.5
|
Safety and
Efficacy
|
11.3.6
|
Product
Profile
|
11.3.7
|
Analysts'
Views
|
11.4
|
BXCL501: BioXcel
Therapeutics Inc.
|
11.4.1
|
Product
Description
|
11.4.2
|
Other Developmental
Activities
|
11.4.3
|
Clinical
Development
|
11.4.4
|
Clinical Trials
Information
|
11.4.5
|
Safety and
Efficacy
|
11.4.6
|
Product
Profile
|
11.4.7
|
Analyst View
|
12
|
Opioid Withdrawal
Syndrome: Market Analysis
|
12.1
|
Key Findings
|
12.2
|
Market
Outlook
|
12.3
|
Conjoint
Analysis
|
12.4
|
Key Market Forecast
Assumptions
|
12.5
|
Total Market Size of
Opioid Withdrawal Syndrome in the 7MM
|
12.6
|
Total Market Size of
Opipoid Withdrawal Syndrome by Therapies in the 7MM
|
12.7
|
Market Size of Opioid
Withdrawal Syndrome in the United States
|
12.7.1
|
Total Market Size of
Opioid Withdrawal Syndrome
|
12.7.2
|
Market size of Opioid
Withdrawal Syndrome by Therapies in the US
|
12.8
|
Market Size of Opioid
Withdrawal Syndrome in EU4 and the UK
|
12.8.1
|
Total Market Size of
Opioid Withdrawal Syndrome
|
12.8.2
|
Market size of Opioid
Withdrawal Syndrome by Therapies in EU4 and the UK
|
12.9
|
Market Size of Opioid
Withdrawal Syndrome in Japan
|
12.9.1
|
Total Market Size of
Opioid Withdrawal Syndrome
|
12.9.2
|
Market size of Opioid
Withdrawal Syndrome by Therapies in Japan
|
13
|
Key Opinion Leaders'
Views
|
14
|
SWOT
Analysis
|
15
|
Unmet Needs
|
16
|
Market Access and
Reimbursement
|
16.1
|
The United
States
|
16.1.1
|
Centers for Medicare
and Medicaid Services (CMS)
|
16.2
|
EU4 and the
UK
|
16.2.1
|
Germany
|
16.2.2
|
France
|
16.2.3
|
Italy
|
16.2.4
|
Spain
|
16.2.5
|
The United
Kingdom
|
16.3
|
Japan
|
16.3.1
|
MHLW
|
17
|
Appendix
|
17.1
|
Bibliography
|
17.2
|
Acronyms and
Abbreviations
|
17.3
|
Report
Methodology
|
18
|
DelveInsight
Capabilities
|
19
|
Disclaimer
|
Related Reports
Opioid Withdrawal Syndrome Pipeline
Opioid Withdrawal Syndrome Pipeline Insight –
2024 report provides comprehensive insights about the
pipeline landscape, pipeline drug profiles, including clinical and
non-clinical stage products, and the key opioid withdrawal
syndrome companies, including Chiesi Farmaceutici S.p.A.,
BioXcel Therapeutics, Aphios Pharmaceutical, among others.
Opioid Withdrawal Syndrome Epidemiology
Opioid Withdrawal Syndrome Epidemiology Forecast –
2034 report delivers an in-depth understanding of the
disease, historical and forecasted opioid withdrawal
syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy,
France, and the United Kingdom), and Japan.
Opioid Use Disorder Market
Opioid Use Disorder Market Insights, Epidemiology, and Market
Forecast – 2034 report delivers an in-depth understanding of
the disease, historical and forecasted epidemiology, as well as the
market trends, market drivers, market barriers, and key opioid use
disorder companies, including Braeburn Pharmaceuticals,
BioXcel Therapeutics, MediciNova, AstraZeneca, Cerevel
Therapeutics, LLC, Indivior Inc., Aptinyx, among others.
Opioid Dependence Market
Opioid Dependence Market Insights, Epidemiology, and
Market Forecast – 2034 report delivers an in-depth
understanding of the disease, historical and forecasted
epidemiology, as well as the market trends, market drivers, market
barriers, and key opioid dependence companies, including GW
Pharmaceuticals, Opiant Pharmaceuticals, ATAI Life Sciences, C4X
Discovery, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market
Research firm focused exclusively on life sciences. It supports
pharma companies by providing comprehensive end-to-end solutions to
improve their performance. Get hassle-free access to all the
healthcare and pharma market research reports through our
subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo:
https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/opioid-withdrawal-syndrome-drug-market-to-surge-at-a-cagr-of-4-0-by-2034--delveinsight-302132673.html
SOURCE DelveInsight Business Research, LLP